Stay updated on CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial

Sign up to get notified when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The value of the revision has been updated from v2.8.1 to v2.9.0, indicating a recent change in the version of the webpage content.
    Difference
    4%
    Check dated 2024-06-21T04:19:22.000Z thumbnail image
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    8 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T22:41:58.000Z thumbnail image
  6. Check
    15 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the safety and efficacy evaluation of CTX130 in subjects with relapsed or refractory T or B cell malignancies.
    Difference
    0.2%
    Check dated 2024-06-06T14:45:57.000Z thumbnail image
  7. Check
    30 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to include detailed eligibility criteria for study participants, specifying age, diagnosis, and health conditions required for inclusion, as well as exclusion criteria such as prior treatments and certain health conditions.
    Difference
    18%
    Check dated 2024-05-22T21:32:41.000Z thumbnail image
  8. Check
    31 days ago
    Change Detected
    Summary
    The value 03 03 03 2023 04 has been updated to 05 05 (Estimated) 05 2024 05 on the webpage, indicating a change in the estimated study completion date from March 2023 to May 2024. This change likely reflects an adjustment in the timeline for the safety and efficacy evaluation of CTX130 in subjects with relapsed or refractory T or B cell malignancies.
    Difference
    0.8%
    Check dated 2024-05-21T16:47:07.000Z thumbnail image
  9. Check
    52 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:33:26.000Z thumbnail image

Stay in the know with updates to CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.